The US Food and Drug Administration (FDA) has granted fast track designation to Moderna’s Covid-19 vaccine candidate, mRNA-1273.
This designation will expedite future reviews of the vaccine as it progresses into later-stage clinical trials. Moderna’s Covid-19 vaccine is currently in Phase I clinical trials, however, the FDA recently authorised the company to conduct a Phase II trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company’s chief medical officer commented: “Fast track designation underscores the urgent need for a vaccine against the novel coronavirus.
“As we await the full set of clinical data from the NIAID-led Phase 1 study, we are actively preparing for our Phase II and Phase III clinical studies to continue learning about the potential of mRNA-1273 to protect against SARS-CoV-2,” the virus that causes Covid-19.
Moderna has received funding from BARDA and CEPI to date to support its accelerated Covid-19 vaccine development programme.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
